Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison

Open access
Cota, Gláucia F., de Sousa, Marcos R., Fereguetti, Tatiani Oliveira, Rabello, Ana·2013·PLoS Neglected Tropical Diseases

Abstract

OBJECTIVE: We conducted a systematic literature review with indirect comparison of studies evaluating therapeutic efficacy and toxicity associated to visceral leishmaniasis (VL) therapy among HIV infected individuals. MAIN OUTCOME MEASUREMENTS: The outcomes of interest were clinical and parasitological cure, mortality, and adverse events. METHODS: PRISMA guidelines for systematic reviews and Cochrane manual were followed. Sources were MEDLINE, LILACS, EMBASE, Web of Knowledge databases and manual search of references from evaluated studies. We included all studies reporting outcomes after VL treatment, regardless of their design. Study quality was evaluated systematically by using the Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Comprehensive Meta-Analysis software v.2.2.048 was used to perform one-group meta-analysis of study arms with the same drug to estimate global rates of success and adverse events with each drug. These estimates were used, when possible, to indirectly compare treatment options, adjusted for CD4 count. Direct comparison was pooled when available. RESULTS: Seventeen studies reporting five treatment regimens and outcome of 920 VL episodes occurring in HIV infected individuals were included. The main outstanding difference in outcome among the treatment regimens was observed in mortality rate: it was around 3 times higher with high-dose antimony use (18.4%, CI 95% 13.3-25%), indirectly compared to lipid formulations of amphotericin B treatment (6.1%, CI 95% 3.9-9.4%). It was observed, also by indirect comparison, higher rates of clinical improvement in study arms using amphotericin B than in study arms using pentavalent antimonial therapy (Sb(v)). The parasitological cure, an outcome that presented some degree of risk of selection and verification bias, had rates that varied widely within the same treatment arm, with high heterogeneity, hampering any formal comparison among drugs. One direct comparison of amphotericin and antimoniate was possible combining results of two studies and confirming the superiority of amphotericin. CONCLUSIONS: Available evidence suggests that amphotericin is superior to antimony treatment. Death rate using antimoniate high dose is unacceptably high. Randomized controlled trials are necessary to compare different formulations and doses of amphotericin, alternative therapies and drug combinations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pntd.0002195

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 38

  1. J Alvar, 2008, The relationship between leishmaniasis and AIDS: the second 10 years, Clin Microbiol Rev, 21, 334, 10.1128/CMR.00061-07 · DOI · Paper page
  2. HW Murray, 2010, Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India, Future Microbiol, 5, 1301, 10.2217/fmb.10.92 · doi:10.2217/fmb.10.92
  3. HW Murray, 2004, Treatment of visceral leishmaniasis in 2004, Am J Trop Med Hyg, 71, 787, 10.4269/ajtmh.2004.71.787 · doi:10.4269/ajtmh.2004.71.787
  4. R Paredes, 2003, Leishmaniasis in HIV infection, J Postgrad Med, 49, 39, 10.4103/0022-3859.929 · DOI
  5. GF Cota, 2011, Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review, PLoS Negl Trop Dis, 5, e1153, 10.1371/journal.pntd.0001153 · doi:10.1371/journal.pntd.0001153
  6. K Ritmeijer, 2001, Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome, Trans R Soc Trop Med Hyg, 95, 668, 10.1016/S0035-9203(01)90110-5 · doi:10.1016/s0035-9203(01)90110-5
  7. R Paredes, 1997, Leishmaniasis in HIV-infected persons: a review, J Int Assoc Physicians AIDS Care, 3, 22
  8. EM Moore, 2010, Treatment of visceral leishmaniasis, J Glob Infect Dis, 2, 151
  9. AM Glenny, 2005, Indirect comparisons of competing interventions, Health Technol Assess, 9, 1
  10. G Gartlehner, 2008, Direct versus indirect comparisons: a summary of the evidence, Int J Technol Assess Health Care, 24, 170, 10.1017/S0266462308080240 · DOI
  11. A Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100 · DOI · Paper page
  12. E Ribera, 1995, Visceral leishmaniasis in patients with HIV infection, Enferm Infecc Microbiol Clin, 13, 73
  13. E Ribera, 1996, Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients, Am J Med, 100, 496, 10.1016/S0002-9343(97)89503-4 · doi:10.1016/s0002-9343(97)89503-4
  14. F Laguna, 1997, Visceral leishmaniasis in patients infected with the human immunodeficiency virus, Eur J Clin Microbiol Infect Dis, 16, 898, 10.1007/BF01700556 · doi:10.1007/bf01700556
  15. C Montalban, 1990, Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS, J Infect, 21, 261, 10.1016/0163-4453(90)93933-J · doi:10.1016/0163-4453(90)93933-j
  16. R Russo, 1996, Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome), The Journal of infection, 32, 133, 10.1016/S0163-4453(96)91343-2 · DOI
  17. R Lopez-Velez, 1998, Serologic cross-reactions to Leishmania infantum using indirect immunofluorescence in HIV+ and HIV- patients with active tuberculosis, Enferm Infecc Microbiol Clin, 6, 130
  18. N Berhe, 1999, HIV viral load and response to antileishmanial chemotherapy in co-infected patients, AIDS, 13, 1921, 10.1097/00002030-199910010-00015 · doi:10.1097/00002030-199910010-00015
  19. F Laguna, 2003, Treatment of leishmaniasis in HIV-positive patients, Ann Trop Med Parasitol, 97, 135, 10.1179/000349803225002606 · DOI
  20. K Ritmeijer, 2006, A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection, Clin Infect Dis, 43, 357, 10.1086/505217 · doi:10.1086/505217
  21. I Molina, 2007, Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients, J Antimicrob Chemother, 60, 837, 10.1093/jac/dkm294 · DOI
  22. PK Sinha, 2011, Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India, Clin Infect Dis, 53, e91, 10.1093/cid/cir521 · doi:10.1093/cid/cir521
  23. K Ritmeijer, 2011, Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence, Clin Infect Dis, 53, e152, 10.1093/cid/cir674 · DOI
  24. F Laguna, 1999, Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group, AIDS, 13, 1063, 10.1097/00002030-199906180-00009 · doi:10.1097/00002030-199906180-00009
  25. J Delgado, 1999, High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients, Am J Trop Med Hyg, 61, 766, 10.4269/ajtmh.1999.61.766 · doi:10.4269/ajtmh.1999.61.766
  26. FM Delgado, 1997, The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection, Ann Med Interne, 14, 506
  27. E Rosenthal, 1995, Visceral leishmaniasis and HIV-1 co-infection in southern France, Trans R Soc Trop Med Hyg, 89, 159, 10.1016/0035-9203(95)90476-X · doi:10.1016/0035-9203(95)90476-x
  28. V Pintado, 2001, Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study, Medicine, 80, 54, 10.1097/00005792-200101000-00006 · doi:10.1097/00005792-200101000-00006
  29. V Pintado, 2001, HIV-associated visceral leishmaniasis, Clin Microbiol Infect, 7, 291, 10.1046/j.1198-743x.2001.00262.x · doi:10.1046/j.1198-743x.2001.00262.x
  30. M den Boer, 2006, Treatment options for visceral leishmaniasis, Expert Rev Anti Infect Ther, 4, 187, 10.1586/14787210.4.2.187 · doi:10.1586/14787210.4.2.187
  31. F Frezard, 2009, Pentavalent antimonials: new perspectives for old drugs, Molecules, 14, 2317, 10.3390/molecules14072317 · DOI
  32. SL Croft, 2002, Curr Pharm Des, Curr Pharm Des, 8, 319
  33. BL Herwaldt, 1992, Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies, The Am J Trop Med Hyg, 46, 296, 10.4269/ajtmh.1992.46.296 · doi:10.4269/ajtmh.1992.46.296
  34. J Adler-Moore, 2002, AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience, J Antimicrob Chemother, 49, 21, 10.1093/jac/49.suppl_1.21 · DOI · Paper page
  35. M Balasegaram, 2012, Liposomal amphotericin B as a treatment for human leishmaniasis, Expert Opin Emerg Drugs, 17, 493, 10.1517/14728214.2012.748036 · DOI · Paper page
  36. S Donegan, 2010, Indirect comparisons: a review of reporting and methodological quality, PloS One, 5, e11054, 10.1371/journal.pone.0011054 · DOI
  37. F Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
  38. F Song, 2011, Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study, BMJ, 343, d4909, 10.1136/bmj.d4909 · DOI · Paper page

Cited by

See all 189

Metadata

Authors
Cota, G. F., de Sousa, M. R., Fereguetti, T. O., & Rabello, A.
Venue
PLoS Neglected Tropical Diseases
Published
2013-05-02
Volume
7
Issue
5
Pages
e2195
ISSN
  • 1935-2727 (ISSN-L)
  • 1935-2735
OpenAlex
W1983173704
Cited by
189
References
1
FWCI
2.72
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison. https://app.cochat.ai/papers/10.1371/journal.pntd.0002195
The paper
Cota, G. F., de Sousa, M. R., Fereguetti, T. O., & Rabello, A. (2013). Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison. PLoS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0002195

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.